MedTrace Logo

Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

NCT06668753 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2024-10-31

No results posted yet for this study

Summary

To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease.

And its role in improvement of Albuminuria and CKD progression.

Conditions

  • Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy

Interventions

DRUG

Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab

SGLT-2 inhibitors

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hussien Ahmed Elamin, PHD · Assiut University

  • Essam Abdel Aziz, PHD · Assiut University

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2026-09-30
Completion
2027-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06668753 on ClinicalTrials.gov